Bayer's Dual Pipeline Boost Meets a Divided Analyst Desk
Published on 10/29/2026 at 05:51 | Editorial boerse-global.de
Bayer packed a lot into a single weekend. On Saturday the German drugs-to-seeds group lifted the lid on an interim analysis of its Phase III DASL-HiCaP trial, and the headline number was striking: darolutamide, layered on top of androgen deprivation therapy and radiotherapy, cut the combined risk of metastases or death by 58% versus placebo.
The compound, marketed as Nubeqa, was tested as an add-on to standard androgen deprivation and radiation treatment. The benefit reported relates specifically to that composite endpoint of metastasis or death. Over a median observation window of 3.8 years, the four-year metastasis-free survival rate reached 95% in the darolutamide arm, compared with 88% for placebo. Bayer was careful to flag that these are interim findings, not the final readout of the study. The treatment setting examined in DASL-HiCaP is not yet an approved indication for darolutamide.
A World-First Approval Out of China
Monday brought a second piece of good news, this time from Asia. China's drug regulator cleared Asundexian — sold there under the name Sunharbo — to reduce stroke risk in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. According to Bayer, it is the first FXIa inhibitor approved anywhere in the world. Reuters framed the drug as a potential successor to the blood thinner Xarelto, which is under pressure from generic competition — making the Chinese green light a strategic as well as a clinical milestone.
Should investors sell immediately? Or is it worth buying Bayer?
Two Banks, Two Very Different Price Targets
The research community, though, is not reading the runes the same way. Michael Leuchten of Jefferies reiterated a Hold rating on Monday, keeping his price target at €46.00. Richard Vosser at J.P. Morgan went the other direction, confirming a Buy and lifting his target to €61.00. The split captures the tension in the story: scientific momentum on one side, commercial execution on the other. Bayer shares closed the prior session at €45.89, just below Jefferies' target.
Ohio Bet Signals a Longer Game
Beyond the near-term catalysts, Bayer is laying groundwork for the long haul. On October 2 the company announced a 2.2 billion US dollar investment in a new pharmaceutical production site in New Albany, Ohio. The plan calls for roughly 600 permanent jobs, plus about 1,500 positions during the construction phase. The first module is slated to come online in 2031, with a second planned for 2034.
Investors will get their next hard look at the numbers on November 3, 2026, when Bayer reports third-quarter results for that year. Until then, the debate is likely to hinge on whether pipeline wins can translate into the revenue line fast enough to satisfy the bulls.
Ad
Bayer Stock: New Analysis - 29 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
